Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

19 trials with published results (8%)

Research Maturity

143 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.0%

15 terminated out of 249 trials

Success Rate

90.5%

+4.0% vs benchmark

Late-Stage Pipeline

3%

8 trials in Phase 3/4

Results Transparency

13%

19 of 143 completed with results

Key Signals

19 with results91% success15 terminated

Data Visualizations

Phase Distribution

157Total
Not Applicable (81)
Early P 1 (5)
P 1 (27)
P 2 (36)
P 3 (1)
P 4 (7)

Trial Status

Completed143
Unknown32
Recruiting32
Terminated15
Not Yet Recruiting7
Active Not Recruiting6

Trial Success Rate

90.5%

Benchmark: 86.5%

Based on 143 completed trials

Clinical Trials (249)

Showing 20 of 20 trials
NCT07239336Phase 2RecruitingPrimary

Study of DONQ52 in Active Celiac Disease

NCT06807463Phase 2Active Not RecruitingPrimary

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

NCT07298343Phase 2RecruitingPrimary

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

NCT04530123Phase 2CompletedPrimary

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT05574010Phase 1TerminatedPrimary

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT07453589Not Yet RecruitingPrimary

Small Bowel Ultrasound and Antibody Levels in Celiac Disease Activity

NCT04477928Recruiting

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

NCT06152289Recruiting

Development of New Diagnostic Tools in Capsule Endoscopy

NCT06557772Phase 2Active Not Recruiting

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT05680012Not ApplicableRecruitingPrimary

Tissue Destruction and Healing in Celiac Disease

NCT07069127Not ApplicableRecruitingPrimary

Hydroxyapatite-Based Home Treatment for Dentin Sensitivity in Celiac Patients

NCT07387185RecruitingPrimary

AI System for Detection and Characterization of Chronic Enteropathies

NCT07377565Phase 1Not Yet RecruitingPrimary

A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07366151Not Yet Recruiting

Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients

NCT07063823Phase 1RecruitingPrimary

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07362654Not ApplicableRecruitingPrimary

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

NCT04806620Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT06310291Early Phase 1RecruitingPrimary

VTP-1000 in Adults With Celiac Disease

NCT04306939Suspended

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT06001177Phase 2CompletedPrimary

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Scroll to load more

Research Network

Activity Timeline